CN104558199A - Preparation and application of fusion protein for treating hypercholesteremia - Google Patents
Preparation and application of fusion protein for treating hypercholesteremia Download PDFInfo
- Publication number
- CN104558199A CN104558199A CN201410454292.6A CN201410454292A CN104558199A CN 104558199 A CN104558199 A CN 104558199A CN 201410454292 A CN201410454292 A CN 201410454292A CN 104558199 A CN104558199 A CN 104558199A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- seq
- polypeptide
- egf
- pcsk9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 10
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 3
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims abstract description 29
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 108010001831 LDL receptors Proteins 0.000 claims abstract description 18
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims abstract description 3
- 230000004927 fusion Effects 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 17
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 210000003494 hepatocyte Anatomy 0.000 abstract description 3
- 102000000853 LDL receptors Human genes 0.000 abstract 3
- 108010075254 C-Peptide Proteins 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000004087 circulation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150038172 1.2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- -1 EGF amino acid Chemical class 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Abstract
The invention discloses a PCSK9-combined fusion protein which is represented by the following general formula: X-connecting peptide-Y-connecting peptide-Z-connecting peptide-IgG Fc segment, wherein X, Y and Z are EGF(A) region polypeptide mutants in LDL-R (low-density lipoprotein receptor), and the connecting peptide is (GGGGS)n. The fusion protein disclosed by the invention can be combined with the PCSK9 at high affinity to inhibit the PCSK9 from degrading the hepatocyte LDL-R and increase the intake of the hepatocytes for LDL-C, and thus, has obvious advantages and favorable prospects in the aspect of treating hypercholesteremia, familial hypercholesteremia and other diseases.
Description
Technical field
The present invention relates to genetically engineered field, be specifically related to preparation of a kind of new fusion protein and uses thereof.
Background technology
Hypercholesterolemia, with Lipoprotein Disorders or blood fat disorder, raises as feature with blood cholesterol levels low-density lipoprotein (LDL) especially, can cause the diseases such as palsy, coronary heart disease, lower limb vascular disease and atherosclerosis.At present, medicine is mainly statins, and such medicine obviously can reduce low density lipoprotein cholesterol (LDL-C), and the risk of LDL-C level and coronary heart disease is closely related.Therefore, reduction LDL-C is the preferred object in current lipid-lowering therapy guide.But the current treatment status of hypercholesterolemia allows of no optimist, major part is high-risk does not all reach LDL-C target value with pole high-risk patient, it can not be made up to standard even if use best statins or increase drug dose.Trace it to its cause, clinical life-time service treatment can stimulate a kind of serine protease-the expression of proprotein convertases subtilysin 9 (PCSK9), PCSK9 is the negative regulator agent of low density lipoprotein receptor (LDL-R), can be accelerated it degrade after being combined with the LDL-R of surface of hepatocytes, liver cell and LDL-R is caused to decline to the picked-up of cholesterol, and then increase the LDL-C level of circulation, finally affect the result for the treatment of of patient.Thus, PCSK9 also becomes the important target spot for the treatment of hypercholesterolemia.
For PCSK9, develop multiple therapeutic monoclonal antibodies abroad, and all in clinical trial, show good curative effect, as the alirocumab that Sai Nuofei and Regeneron jointly develops, Amgen like product evolocumab, all significantly reduces the LDL-C level of health volunteer, familial hyperlipidemia patient and non-Familial HypercholesterolemicPatients Patients; For the patient of statins poor effect, after injection monoclonal antibody, its blood LDL-C level also reduces 40%-72%.
Monoclonal antibody good therapeutic action inspire people think deeply and develop more spininess to the new drug of PCSK9, as research find, the EGF-A district of recombinant soluble LDL-R can block combination and the interaction of PCSK9 and LDL-R, and reach reduction cholesterol object; Patent (application number: 20128003049.9) disclose a kind of polypeptide in conjunction with PCSK9 and using method thereof, comprises epidermal growth factor domain (EGF-A) and mutant thereof, and with the ability of the high affine combination of PCSK9.In addition, disturb the effect that also obviously can block PCSK9 at gene level by antisense nucleic acid and RNA, even adopt micromolecular compound to suppress the mrna expression of PCSK9, also obviously can reduce the effect of cholesterol.Obviously, the method for various blocking-up PCSK9 all may become the anti-PCSK9 new drug after therapeutic monoclonal antibody.
The invention provides a kind of recombinant soluble EGF-A mutant fusion protein, this fusion rotein can be high affine in conjunction with PCSK9, and can effectively suppress PCSK9 biological activity, the final effect playing reduction cholesterol.
Summary of the invention
The object of this invention is to provide a kind of fusion rotein, this fusion rotein is replaced/is suddenlyd change for the amino acid in EGF in LDLR (A) district and human IgG FC fusion rotein (representing with 3mEGF-FC), strengthen the keying action of EGF-FC and PCSK9, effectively suppress PCSK9 active.
Fusion rotein provided by the invention is realized by DNA recombinant technology or genetic engineering means, and expressed by the following formula:
X-connection peptides-Y-connection peptides-Z-connection peptides-IgG Fc fragment; Wherein, X, Y, Z are EGF (A) polypeptide mutant in people LDLR (low density lipoprotein receptor); Connection peptides is (GGGGS) n.
Fusion rotein provided by the invention, be connected to form fusion rotein by EGF (A) district's polypeptide mutant in people LDLR and human normal immunoglobulin Fc fragment, its concrete sequence is as follows:
The amino acid of EGF (A) polypeptide mutant is as described in the SEQ ID NO:1,3,5 in sequence table;
The amino acid of IgG1 Fc is as described in the SEQ ID NO:15 in sequence table;
The amino acid of IgG2 Fc is as described in the SEQ ID NO:17 in sequence table;
The amino acid of IgG3 Fc is as described in the SEQ ID NO:19 in sequence table;
The amino acid of IgG4 Fc is as described in the SEQ ID NO:21 in sequence table.
3mEGF-FC fusion rotein Nucleotide is as described in the SEQ ID NO:23 in sequence table.
Described above-mentioned fusion rotein nucleotide sequence of encoding is as follows:
The Nucleotide of EGF (A) is as described in the SEQ ID NO:2,4,6 in sequence table;
The Nucleotide of IgG1 Fc is as described in the SEQ ID NO:16 in sequence table;
The Nucleotide of IgG2 Fc is as described in the SEQ ID NO:18 in sequence table;
The Nucleotide of IgG3 Fc is as described in the SEQ ID NO:20 in sequence table;
The Nucleotide of IgG4 Fc is as described in the SEQ ID NO:22 in sequence table.
3mEGF-FC fusion rotein Nucleotide is as described in the SEQ ID NO:24 in sequence table.
Invention also provides the expression vector of above-mentioned nucleotide sequence, it can copy expression in transformed host cell.
Present invention also offers a kind of method preparing fusion rotein, above-mentioned expression vector is introduced suitable expression system, thus carry out the expression of fusion rotein.
Invention further provides a kind of pharmaceutical composition, it is made up of above-mentioned fusion rotein and pharmaceutically acceptable carrier or vehicle; The dosage form of described pharmaceutical composition is preferably injection, injection freeze-dried powder.
Present invention also offers above-mentioned fusion rotein and prepare the purposes in the disease medicaments such as prevention and therapy hypercholesterolemia, familial hypercholesterolemia, the metabolic disease that brought out by PCSK9.
The expression vector of fusion rotein of the present invention can be recombinant eukaryon expression vector, preferred mammal fibrocyte expression vector; Also can be recombinant virus expression vector, preferred adeno-associated virus or adenovirus carrier.
Containing expressing the host cell of above-mentioned fusion rotein, can be DG44, Chinese hamster ovary celI and subbreed thereof or 293 cells and subbreed thereof.
Accompanying drawing explanation
Fig. 1 fusion rotein of the present invention is on the impact of PCSK9 degraded liver cell LDL-R
Fig. 2 fusion rotein of the present invention is on the impact of liver cell picked-up LDL-C
Embodiment
Following examples are provided to be further explained the present invention.Should be appreciated that these embodiments only have any restriction for illustration of the present invention to the present invention.Those skilled in the art under the enlightenment of this specification sheets to the invention process in any variation of doing all will drop in the scope of claims.
The preparation of embodiment 1 fusion rotein
1, plasmid construction
1.1 genes and primer synthesis
Expressed sequence by the gene of following synthesis and primer restructuring to expression vector.Gene and primer are synthesized by Beijing Jin Weizhi company of specialized company, and synthetic gene sequence is recombinated in plasmid vector pUC19, called after pUC19-EGFwt, pUC19-mEGF
14, pUC19-mEGF
16with pUC19-3M EGF.
Synthesis fusion protein gene fraction:
EGFwt：
ATCACCGGTATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGGACTGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGACAAAACTCACACATGCCCAC
mEGF
14：
ATCACCGGTATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGGACTGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCTACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGACAAAACTCACACATGCCCAC
mEGF
16：
ATCACCGGTATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGGACTGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTACAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGACAAAACTCACACATGCCCAC
3mEGF：
CCTAGGGCCACCATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGGACTGGGACCAGCGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTACAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCCGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGGCGGCGGCGGCTCCGGAGGAGGAGGATCCGGAGGAGGAGGATCCGACAAAACTCACACATGCCCAC
Synthetic primer:
E1：5’-ATCCCTAGGGCCACCATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTC-3’
E2：5’-GTGGGCATGTGTGAGTTTTGTCGGATCCT-3’
E3：5’-GACAAAACTCACACATGCCCACCGTGC-3’
E4：5’-GTCGTATACTCATTTACCCGGAGACAGGGA-3’
The amplification of 1.2 gene fragments
Special primer E1 and E2 is utilized to obtain partial gene fragments by PCR method amplification.PCR reaction system 1 (cumulative volume 50 μ l): 5 × Buffer 10 μ l, dNTP 2 μ l, primer 1 μ l (E1 and E2), template are respectively synthesis fragment pUC19-EGFwt, pUC19-mEGF
14, pUC19-mEGF
16with pUC19-3mEGF plasmid 1 μ l, Phusion enzyme 0.5 μ l, finally mend to 50 μ l with distilled water; Reaction conditions: 98 DEG C of denaturation 30s, 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 30s, 30 circulations, last 72 DEG C of 5min.Gene product detects with agarose gel electrophoresis, obtains gene fragment called after EGFwt, mEGF
14, mEGF
16and 3mEGF.
Special primer E3 and E4 is utilized to obtain partial gene fragments by PCR method amplification.PCR reaction system 2 (cumulative volume 50 μ l): 5 × Buffer 10 μ l, dNTP 2 μ l, primer 1 μ l (E3 and E4), template are pFUSE-hIgG1-Fc plasmid 1 μ l, Phusion enzyme 0.5 μ l, finally mends to 50 μ l with distilled water; Reaction conditions: 98 DEG C of denaturation 30s, 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 30s, 30 circulations, last 72 DEG C of 5min.Gene product detects with agarose gel electrophoresis, obtains gene fragment called after Fc.
Special primer E1 and E4 is utilized to obtain goal gene fragment by the amplification of bridge joint PCR method.PCR reaction system 3 (cumulative volume 50 μ l): 5 × Buffer 10 μ l, dNTP 2 μ l, primer 1 μ l (P1 and P2), template are above-mentioned amplification gene fragment EGFwt, mEGF
14, mEGF
16, 3mEGF respectively with Fc mix each 1 μ l, Phusion enzyme 0.5 μ l, finally with distilled water mend to 50 μ l; Reaction conditions: 98 DEG C of denaturation 30s, 98 DEG C of 10s, 68 DEG C of 60s, 3 circulations, 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 50s, 30 circulations, last 72 DEG C of 5min.Gene product detects with agarose gel electrophoresis, obtains gene fragment called after EGFwt-Fc, mEGF
14-Fc, mEGF
16-Fc and 3mEGF-Fc.
The enzyme of 1.3 carriers and gene fragment cuts process
To pCHO1.0 plasmid and EGFwt-Fc, mEGF
14-Fc, mEGF
16-Fc and 3mEGF-Fc gene fragment carry out double digestion process respectively, and enzyme cuts the foundation of system: in 1.5ml EP pipe, add following composition: enzyme cuts the foundation of system 1: in 1.5mlEP pipe, add following composition: pCHO1.0 plasmid or EGFwt-Fc, mEGF
14-Fc, mEGF
16-Fc and 3mEGF-Fc gene fragment 40 μ l, each 5 μ l of Buffer410 μ l, Avr II and BstZ17I, aqua sterilisa 45 μ l, reacts 5h after mixing at 37 DEG C, utilizes QIAGEN Product Purification Kit to reclaim.
The connection of 1.4 recombinant plasmids transforms
Under the effect of T4 ligase enzyme, by with same enzyme cut rear reclaim obtain gene fragment pCHO1.0 (Avr II and BstZ17I) large fragment cut through with enzyme respectively after EGFwt-Fc (Avr II and BstZ17I), mEGF
14-Fc (Avr II and BstZ17I), mEGF
16-Fc (Avr II and BstZ17I) is connected with 3mEGF-Fc (Avr II and BstZ17I) gene fragment.Ligation system is as follows: in 1.5ml EP pipe, add following composition pCHO1.0 (Avr II and BstZ17I) 2 μ l, EGFwt-Fc (Avr II and BstZ17I) or mEGF
14-Fc (Avr II and BstZ17I) or mEGF
16-Fc (Avr II and BstZ17I) or 3mEGF-Fc (Avr II and BstZ17I) 6 μ l, 10 × T4 Buffer 1 μ l, T4 DNA ligase 1 μ l, under room temperature (about 20 DEG C), more than 4h is reacted after mixing, connect product conversion in Top10 competent escherichia coli cell, coat 37 DEG C of left undisturbed overnight on 2YT (KANA) plate culture medium, dull and stereotyped numbering pCHO-EGFwt-Fc, pCHO-mEGF
14-Fc, pCHO-mEGF
16-Fc and pCHO-3mEGF-Fc.
The bacterium colony PCR of 1.5 recombinant plasmids screens
From pCHO-EGFwt-Fc, pCHO-mEGF
14-Fc, pCHO-mEGF
16in-Fc and pCHO-3mEGF-Fc flat board, the single bacterium colony of the several restructuring of each picking is as pcr template after cultivating, and carries out PCR Screening and Identification respectively.Bacterium liquid pcr amplification reaction system (cumulative volume 20 μ L): 2 × Taq HS 10 μ L, bacterium liquid template 2 μ L, each 1 μ L of upstream and downstream primer (E1 and E4) (final concentration 0.3 μm of ol/L), finally mends to 20 μ L with distilled water; Reaction conditions: 95 DEG C of 3min, 94 DEG C of 60s, 53 DEG C of 60s, 72 DEG C of 90s, 30 circulations; Last 72 DEG C of 5min.Agarose gel electrophoresis analytical results.
The enzyme of 1.6 recombinant plasmids cuts qualification
Extract after identifying correct colony inoculation by bacterium colony PCR and carry out enzyme again and cut qualification.First carry out the plasmid extraction of recombinant bacterium, then carry out restriction analysis, enzyme cuts system: in 1.5ml EP pipe, add following composition: plasmid 2 μ l, the each 1 μ l of Buffer11 μ l, BSA0.1 μ l, Avr II and BstZ17I, mend aqua sterilisa to 10 μ l, after mixing, at 37 DEG C, react 4h.Agarose gel electrophoresis analytical results.
The order-checking qualification of 1.7 recombinant plasmids
Identify that correct bacterium colony is inoculated several bacterium colony at random and carried out order-checking qualification again by being cut by bacterium colony PCR and enzyme.There is provided bacterium liquid sample recombinant plasmid to deliver to company and carry out order-checking qualification.Expression plasmid saves backup.
2, plasmid transfection and cell screening
Plasmid extraction adopts QIAGEN Plasmid Midi Kit, adopts host cell CHO-S or DG44, according to Freedom
tMcHO-S
tMkit test kit specification sheets carries out plasmid transfection respectively.The cell proceeding to plasmid is placed in shake-flask culture (37 DEG C, 8%CO2,110rpm/min) respectively to 48h, and cell counter detects Cell viability and cell count.
Two step pressurization screenings are carried out: 10P/100M, 20P/200M (P=10 μ g/mL Puromycin, M=nM MTX) after transfection 48h; 30P/500M, 50P/1000M, obtain just sieve cell.Carry out monoclonal cell screening with limiting dilution assay, therefrom preferably clone enlarged culturing step by step by detection expressing quantity and purity.
3, Protein expression and purification
Screening High producing clones cell expands to 24 orifice plate growths from 96 orifice plates, then expands to 6 orifice plate growths, expands afterwards to 50mL Shake flask grown.
Collect cultivation 7 days cell culture supernatants, centrifugal removing cell debris, supernatant liquor is with 0.45 μm of membrane filtration, regulate pH to 7.4, with HiTrap Protein-A Sepharose affinity column purified fusion protein, the deionized water rinsing pillar of 5 times of column volumes, use PBS damping fluid (the 20mM phosphoric acid salt of 5 times of column volumes again, pH 7.4) balance pillar, loading, collection effluent liquid detects, with 10 times of volume PBS damping fluid (0.02mol/L phosphoric acid salt, pH 7.4) wash except foreigh protein removing, then 0.1M glycine buffer (pH3) is used by target protein from wash-out post, purity of protein is detected more than 90% with SDS-PAGE.
Embodiment 2 fusion rotein biological activity determination
The binding affinity of EGF-Fc fusion rotein and PCSK9 is determined at Otect QK (Fortebio) by microbial film interferometric method and above measures.SA sensor sensor (Fortebio, article No. 18-5063) be cured in containing the PCSK9 in TrisHCl pH 7.4 damping fluid of 0.5%BSA and 1mM CaCl2, wash in same buffer, and to be transferred to containing concentration in same buffer be in the hole of EGF-FC fusion rotein of 0-500nM.Signal for the reference hole only containing damping fluid is deducted from all in conjunction with data.Avidity KD uses Octet software to obtain by fitting to steady-state algorithm.Summarize the KD value display of determination in tablei: compared with EGFwt-Fc, the avidity of mEGF-Fc mutant and 3mEGF-FC series connection mutein fusion protein increases by 15 to 50 times.
Table I, the binding affinity of EGFwt-Fc, mEGF-Fc mutant and 3mEGF-FC series connection sudden change and PCSK9.KD value is by being that steady-state equation is determined by data fitting.Data represent with mean ± SD.
| Recombination fusion protein | K DValue (nM) |
| EGFwt-Fc | 798±90 |
| mEGF 14-Fc | 121±14 |
| mEGF 16-Fc | 58±9 |
| 3mEGF-Fc | 17±4 |
Embodiment 3 fusion rotein biological activity determination
Human hepatoma HepG2 cell is cultured to logarithmic phase, washes cell once with PBS, and making cell suspension through trysinization and adjust cell density is 1 × 10
6cells/ml.Inoculating cell is in 96 well culture plates (100 μ l/ hole), and marginal pore adds 200 μ l substratum.Put culture plate in 37 DEG C, 5%CO
2in incubator, continue cultivation 24 hours.Remove cells and supernatant, every hole adds 100 μ l serum-free cell culture mediums, and CO2 incubator continues cultivation 16 hours; Abandon supernatant, again change serum-free cell culture medium into, add PCSK9 (final concentration 25 μ g/ml), add EGFwt-FC (10 ~ 50 μMs) respectively or 3mEGF-Fc (03 ~ 3 μM) puts 37 DEG C simultaneously, 5%CO2 incubator hatches 4 hours; Add again
(final concentration is 6 μ g/ml) hatches 3h, removes supernatant, and rinse cell 3 times with PBS, observe under being placed in inverted fluorescence microscope and obtain image, the result that obtains carries out fluorescent quantitation again; Get cell in addition according to preceding method process cell, add PCSK9 (final concentration 25 μ g/ml) and EGFwt-FC (10 ~ 50 μMs) or 3mEGF-Fc (03 ~ 3 μM) effect respectively after 4 hours, harvested cell, adopt immunofluorescence technique, observe expression or the degraded of LDL-R, and carry out fluorescent quantitation.
Intervene PCSK9 process HepG2 cell with EGFwt-FC and 3mEGF-Fc fusion rotein provided by the invention, result shows, EGFwt-FC and 3mEGF-Fc fusion rotein of the present invention all can obviously suppress PCSK9 to the degraded (Fig. 1) of LDL-R; Consistent therewith, EGFwt-FC and 3mEGF-Fc of the present invention also obviously increases liver cell to the picked-up (Fig. 2) of LDL-C, the effect that 3mEGF-Fc suppresses PCKS9 activity and increase liver cell to absorb LDL-C is the most obvious, and present significant concn dependence, illustrate and obviously strengthened by the 3mEGF-FC biological activity of EGF amino acid mutation.
Claims (10)
1. a recombination fusion protein, it is characterized in that described fusion egg can in conjunction with PCSK9, suppress PCSK9 biological activity, its fusion rotein is expressed by the following formula:
X-connection peptides-Y-connection peptides-Z-connection peptides-IgG Fc fragment; Wherein, X, Y, Z are EGF (A) district (epidermal growth factor domain) polypeptide mutant of LDLR (low density lipoprotein receptor); Connection peptides is (GGGGS) n.
2. fusion rotein according to claim 1, is characterized in that polypeptide X is that the 3rd, EGF (A) district l-asparagine is by the polypeptide mutant of any aminoacid replacement; Polypeptide Y is by EGF (A) district) the 16th half Guang acid amides be by the polypeptide mutant of any aminoacid replacement; Polypeptide Z by the 26th, EGF (A) district leucine by the polypeptide mutant of any aminoacid replacement, and combination.
3. the fusion rotein according to claim 1,2, it is characterized in that polypeptide X is EGF (A) district) the 3rd l-asparagine be preferably by polypeptide mutant that Serine replaces, its aminoacid sequence is SEQ ID NO:1, and nucleotides sequence is classified as SEQ ID NO:2; Polypeptide Y is by the 16th, EGF (A) district half Guang acid amides preferably by the polypeptide mutant that tyrosine replaces, and its aminoacid sequence is SEQ ID NO:3, and nucleotides sequence is classified as SEQ ID NO:4; Polypeptide Z is by the 26th, EGF (A) district leucine preferably by the polypeptide mutant that proline(Pro) replaces, and its aminoacid sequence is SEQ ID NO:5, and nucleotides sequence is classified as SEQ ID NO:6, and combination.
4. fusion rotein according to claim 1, wherein connection peptides contains by formula (Gly-Gly-Gly-Gly-Ser) n (in formula, n is the integer of 1 ~ 4), the aminoacid sequence of expression.
5. fusion rotein according to claim 1, wherein Fc fragment is human IgG1 Fc fragment, IgG2 Fc fragment, IgG3 Fc fragment and IgG4 Fc fragment; Its aminoacid sequence is difference SEQ ID NO:15,17,19,21, and nucleotides sequence is classified as SEQ ID NO:16,18,20,22.
6. fusion rotein according to claim 1, its aminoacid sequence is made up of the aminoacid sequence of SEQ ID NO:23 or deleted by one or several amino acid in the aminoacid sequence of SEQ ID NO:23, the aminoacid sequence composition adding and/or replace.
7. prepare the method merging egg, it is characterized in that fusion rotein coding DNA according to claim 1 to insert expression vector, and this carrier is introduced suitable expression system, and carry out the expression of fusion rotein.
8. fusion rotein according to claim 1, is characterized in that fusion rotein forms with pharmaceutically acceptable carrier or vehicle according to any one of claim 1.
9. pharmaceutical composition according to claim 8, is characterized in that the dosage form of described pharmaceutical composition is injection, injection freeze-dried powder.
10., according to right 1-9, it is characterized in that fusion rotein is for prevention and therapy hypercholesterolemia, familial hypercholesterolemia, the metabolic disease etc. that brought out by PCSK9, and with the combined utilization of statins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410454292.6A CN104558199B (en) | 2014-09-05 | 2014-09-05 | A kind of fusion protein preparation for treating hypercholesterolemia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410454292.6A CN104558199B (en) | 2014-09-05 | 2014-09-05 | A kind of fusion protein preparation for treating hypercholesterolemia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104558199A true CN104558199A (en) | 2015-04-29 |
| CN104558199B CN104558199B (en) | 2018-07-06 |
Family
ID=53075348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410454292.6A Active CN104558199B (en) | 2014-09-05 | 2014-09-05 | A kind of fusion protein preparation for treating hypercholesterolemia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104558199B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623672A (en) * | 2017-03-25 | 2018-10-09 | 成都贝爱特生物科技有限公司 | The combination mutant of new EGF-A and B prepares and its application in bio-pharmaceutical |
| CN109295081A (en) * | 2018-10-17 | 2019-02-01 | 中国人民解放军第四军医大学 | A kind of LDLR-Lamp2b fusion, expression vector and its application |
| US11649269B2 (en) | 2018-10-05 | 2023-05-16 | Novo Nordisk A/S | Bifunctional compounds comprising insulin peptides and EGF(A) peptides |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003568A (en) * | 2006-12-20 | 2007-07-25 | 吉林农业大学 | Recombined diphtheria toxin, preparation method, and application |
| CN102232088A (en) * | 2007-10-26 | 2011-11-02 | 先灵公司 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
| CN102612558A (en) * | 2009-09-03 | 2012-07-25 | 辉瑞疫苗有限责任公司 | Pcsk9 vaccine |
| WO2013170367A1 (en) * | 2012-05-17 | 2013-11-21 | The University Of British Columbia | Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors |
-
2014
- 2014-09-05 CN CN201410454292.6A patent/CN104558199B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003568A (en) * | 2006-12-20 | 2007-07-25 | 吉林农业大学 | Recombined diphtheria toxin, preparation method, and application |
| CN102232088A (en) * | 2007-10-26 | 2011-11-02 | 先灵公司 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
| CN102612558A (en) * | 2009-09-03 | 2012-07-25 | 辉瑞疫苗有限责任公司 | Pcsk9 vaccine |
| WO2013170367A1 (en) * | 2012-05-17 | 2013-11-21 | The University Of British Columbia | Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| MATTHEW J. BOTTOMLEY: "Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| YAN G. NI: "A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo", 《JOURNAL OF LIPID RESEARCH 》 * |
| 刘宝全: "多肽基因串联体构建技术", 《安徽农业科学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623672A (en) * | 2017-03-25 | 2018-10-09 | 成都贝爱特生物科技有限公司 | The combination mutant of new EGF-A and B prepares and its application in bio-pharmaceutical |
| US11649269B2 (en) | 2018-10-05 | 2023-05-16 | Novo Nordisk A/S | Bifunctional compounds comprising insulin peptides and EGF(A) peptides |
| CN109295081A (en) * | 2018-10-17 | 2019-02-01 | 中国人民解放军第四军医大学 | A kind of LDLR-Lamp2b fusion, expression vector and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104558199B (en) | 2018-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA47428C2 (en) | Process for controlling sialic acid content, process for preparation of chimerical glycoprotein (variants), a preparation containing chimerical glycoprotein (variants), a therapeutic composition | |
| Sekhon | Biopharmaceuticals: an overview | |
| CN106632682A (en) | Fusion protein IFN-ELP and application thereof | |
| CN102470156A (en) | Polypeptides selective for av ss3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof | |
| CN107261124B (en) | Preparation method and application of angiogenesis inhibiting peptide and hyaluronic acid modifier thereof | |
| EP2910632A1 (en) | NOVEL HIGH-FUNCTIONING ENZYME HAVING ALTERED HUMAN ß-HEXOSAMINIDASE B SUBSTRATE SPECIFICITY, AND HAVING PROTEASE RESISTANCE APPLIED THERETO | |
| CN110066782A (en) | The substantially recombinant furin and its production method of animal protein-free | |
| CN105111314A (en) | Novel fusion protein, pharmaceutical composition and preparation method therefor and use thereof | |
| CN104558199A (en) | Preparation and application of fusion protein for treating hypercholesteremia | |
| CN108137672B (en) | Method for producing fusion proteins with IGG FC domains | |
| CN102153653A (en) | Fusion protein of tumor blood vessel targeted polypeptide and tissue factor and preparation method thereof | |
| CN103757026A (en) | Gene sequence and polypeptide of FGFR2b ectodomain and application thereof | |
| CN101580817A (en) | Method for preparing cell group containing cytokine-induced killing cell | |
| CN104177492B (en) | FGFR2c extracellular domain analog, and coding gene and application thereof | |
| CN101134105A (en) | Pharmaceutical composition containing recombination human pancreatic kininogenase for treating and/or preventing cerebral infarction | |
| CN101245106B (en) | Anti-VRGF acceptor monoclone antibody, preparation method and application thereof | |
| CN102471794B (en) | Method of increasing the expression yield of vitamin k-dependent proteins | |
| CN109402130A (en) | A kind of recombinant human horny cell growth factor-2-1 and its preparation method and application | |
| CN102911958A (en) | Gene for coding recombinant human TNFR-Fc fusion protein and application of gene | |
| CN101134953A (en) | Recombinant human pancreas kininogenase | |
| CN104558198A (en) | Preparation method and application of fusion protein of GLP-1 analogue and amylin analogue | |
| CN101497656A (en) | Polypeptide with high combination activity with integrin alpha v beta 3 and use thereof | |
| CN109097363B (en) | Biological recombinant miR34a-5p capable of effectively inhibiting growth of osteosarcoma | |
| CN108101984B (en) | The preparation method and purposes of osteosclerosis albumen single-chain antibody | |
| CN101967468A (en) | Recombinant human kallidinogenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170602 Address after: 610036 Jinniu District, Sichuan, Sichuan West Road, No. 36, No. Applicant after: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. Address before: 610041 No. 404, building C1, Tianfu Life Science Park, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Applicant before: CHENGDU BIPROTEIN BIOTECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231027 Address after: Room 306, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: Beijing Kanghong Biomedical Co.,Ltd. Address before: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. |
|
| TR01 | Transfer of patent right |